Pfizer Announces Successful Late-Stage Trial for Multiple Myeloma Drug Elrexfio
Pfizer (PFE) has reported positive topline results from a late-stage clinical trial evaluating its multiple myeloma therapy, Elrexfio (elranatamab). The study focused on the drug's efficacy when utilized in an earlier-line treatment setting for patients battling this hematological cancer. The successful outcome marks a significant milestone for Pfizer as it seeks to expand the therapeutic application of elranatamab. If regulatory approvals follow, this expansion could significantly increase the drug's market reach and address unmet needs in earlier stages of multiple myeloma treatment.
Tickers: $PFE
Topics: clinical trial success drug development multiple myeloma
Read the full article at Seeking Alpha
Part of the story FDA Approves Pfizer's Talzenna and Xtandi Combination for Metastatic Hormone-Sensitive Prostate Cancer (2 articles)